Comparison of Adverse Effects of Combination Therapy of Mpox With Tecovirimat and Brincidofovir, and Individual Therapy With Tecovirimat

Abstract

This study evaluates the safety profile of tecovirimat monotherapy compared to its combination with brincidofovir for mpox treatment Brincidofovir is associated with hepatic toxicity, raising concerns about its clinical use Tecovirimat demonstrates a favorable safety profile with minimal side effects, making it a strong candidate for standalone mpox treatment Combining tecovirimat with brincidofovir may increase hepatic toxicity risks and impair drug absorption, necessitating careful consideration A retrospective UK study found that brincidofovir-treated patients experienced liver enzyme abnormalities and prolonged hospitalization, while those on tecovirimat had no major adverse effects Tecovirimat remains the preferred option for mpox management, but further studies are required to establish safer and more effective treatment strategies.